ArticlePDF Available

Empiric Antibiotic Treatment Reduces Mortality in Severe Sepsis and Septic Shock From the First Hour

Authors:

Abstract and Figures

Compelling evidence has shown that aggressive resuscitation bundles, adequate source control, appropriate antibiotic therapy, and organ support are cornerstone for the success in the treatment of patients with sepsis. Delay in the initiation of appropriate antibiotic therapy has been recognized as a risk factor for mortality. To perform a retrospective analysis on the Surviving Sepsis Campaign database to evaluate the relationship between timing of antibiotic administration and mortality. Retrospective analysis of a large dataset collected prospectively for the Surviving Sepsis Campaign. One hundred sixty-five ICUs in Europe, the United States, and South America. A total of 28,150 patients with severe sepsis and septic shock, from January 2005 through February 2010, were evaluated. Antibiotic administration and hospital mortality. A total of 17,990 patients received antibiotics after sepsis identification and were included in the analysis. In-hospital mortality was 29.7% for the cohort as a whole. There was a statically significant increase in the probability of death associated with the number of hours of delay for first antibiotic administration. Hospital mortality adjusted for severity (sepsis severity score), ICU admission source (emergency department, ward, vs ICU), and geographic region increased steadily after 1 hour of time to antibiotic administration. Results were similar in patients with severe sepsis and septic shock, regardless of the number of organ failure. The results of the analysis of this large population of patients with severe sepsis and septic shock demonstrate that delay in first antibiotic administration was associated with increased in-hospital mortality. In addition, there was a linear increase in the risk of mortality for each hour delay in antibiotic administration. These results underscore the importance of early identification and treatment of septic patients in the hospital setting.
Content may be subject to copyright.
Copyright (c) Society of Critical Care Medicine and Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited
Critical Care Medicine www.ccmjournal.org 1
grant support from Pulsion. The remaining authors have disclosed that
they do not have any potential conflicts of interest.
For information regarding this article, E-mail: mitchell_levy@brown.edu
Objectives: Compelling evidence has shown that aggressive
resuscitation bundles, adequate source control, appropriate anti-
biotic therapy, and organ support are cornerstone for the success
in the treatment of patients with sepsis. Delay in the initiation of
appropriate antibiotic therapy has been recognized as a risk factor
for mortality. To perform a retrospective analysis on the Surviving
Sepsis Campaign database to evaluate the relationship between
timing of antibiotic administration and mortality.
Design: Retrospective analysis of a large dataset collected pro-
spectively for the Surviving Sepsis Campaign.
Setting: One hundred sixty-five ICUs in Europe, the United States,
and South America.
Patients: A total of 28,150 patients with severe sepsis and septic
shock, from January 2005 through February 2010, were evaluated.
Interventions: Antibiotic administration and hospital mortality.
Measurements and Main Results: A total of 17,990 patients
received antibiotics after sepsis identification and were included
in the analysis. In-hospital mortality was 29.7% for the cohort as a
whole. There was a statically significant increase in the probability
of death associated with the number of hours of delay for first
antibiotic administration. Hospital mortality adjusted for severity
(sepsis severity score), ICU admission source (emergency depart-
ment, ward, vs ICU), and geographic region increased steadily
after 1 hour of time to antibiotic administration. Results were simi-
lar in patients with severe sepsis and septic shock, regardless of
the number of organ failure.
Conclusions: The results of the analysis of this large population
of patients with severe sepsis and septic shock demonstrate
that delay in first antibiotic administration was associated with
increased in-hospital mortality. In addition, there was a linear
1Department of Intensive Care, Mútua Terrassa University Hospital, CIB ER
Enfermedades Respiratorias, Barcelona, Spain.
2Critical Care Center, Sabadell Hospital, CIBER Enfermedades Respi-
ratorias, Corporacion Sanitaria Universitaria Parc Tauli, Autonomous
University of Barcelona, Sabadell, Spain.
3The Ohio State University Center for Biostatistics, Columbus, OH.
4Department of Surgery and Emergency Medicine, Division of Acute Care
Surgery, Surgical/Trauma Critical Care, Barnes Jewish Hospital, Wash-
ington University, St. Louis, MO.
5California Pacific Medical Center, San Francisco, CA.
6Brown University/Rhode Island Hospital, Providence, RI.
7Cooper University Hospital, Camden, NJ.
Dr. Levy had full access to all the data in the study and takes responsibility
for the integrity of the data and the accuracy of the data analysis.
Supplemental digital content is available for this article. Direct UR L cita-
tions appear in the printed text and are provided in the HTML and PDF
versions of this article on the journal’s website (http://journals.lww.com/
ccmjournal).
Initial funding for the Surviving Sepsis Campaign (from 2002 to 2006)
was through unrestricted educational grants from Eli Lilly, Edwards Life-
sciences, Phillips Medical Systems, and the Coalition for Critical Care
Excellence (Society of Critical Care Medicine). There was no involvement
by the sponsors in the development, data analysis, or manuscript prepara-
tion of the current study. No additional funding has been received since
that time or during the analysis and development of the current study and
manuscript.
Dr. Ferrer served as board member for Laboratorios Ferrer and lectured
for Merck, Sharp and Dohme and Pfizer. His institution received grant
support from Instituto de Salud Carlos III. Mr. Phillips received sup-
port for participation in review activities from the Rhode Island Hospi-
tal, a Lifespan Partner. His institution received grant support from the
National Institutes of Health Grant and Murdoch Children’s Research
Institution. Dr. Osborn consulted for Institute of Healthcare Improvement
(sepsis consultant on quality initiative); received support for travel from
American College of Emergency Physicians (Scientific Assembly 2011,
2012, 2013. Dr. Townsend received support for article research from
the Gordon and Betty Moore Foundation. Dr. Dellinger received support
for travel for the meeting of Surviving Sepsis Campaign (SSC) steer-
ing committee. Dr. Artigas served as board member for Ferrer Farma;
consulted for Hill Rom; and lectured for Pulsion. His institution received
Copyright © 2014 by the Society of Critical Care Medicine and Lippincott
Williams & Wilkins
DOI: 10.1097/CCM.0000000000000330
Empiric Antibiotic Treatment Reduces Mortality
in Severe Sepsis and Septic Shock From the
First Hour: Results From a Guideline-Based
Performance Improvement Program
Ricard Ferrer, MD, PhD1; Ignacio Martin-Loeches, MD, PhD2; Gary Phillips, MAS3;
Tiffany M. Osborn, MD, MPH4; Sean Townsend, MD5; R. Phillip Dellinger, MD, FCCP, FCCM6;
Antonio Artigas, MD, PhD2; Christa Schorr, RN, MSN6; Mitchell M. Levy, MD, FCCP, FCCM7
Copyright (c) Society of Critical Care Medicine and Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited
Ferrer et al
2 www.ccmjournal.org XXX2014•VolumeXX•NumberXXX
increase in the risk of mortality for each hour delay in antibiotic
administration. These results underscore the importance of early
identification and treatment of septic patients in the hospital set-
ting. (Crit Care Med 2014; XX:00–00)
Key Words: antibiotics; knowledge translation; performance
improvement; performance metrics; sepsis; septic shock; severe
sepsis
Sepsis is a worldwide syndrome that affects over 700,000
patients per year in the United States (1), with a high
fatality rate, significant morbidity, and socioeconomic
cost (2). Compelling evidence has shown that aggressive resus-
citation bundles, adequate source control, appropriate anti-
biotic therapy, and organ support are cornerstones for the
success in the treatment of patients with sepsis (3). Delay in
the initiation of appropriate antibiotic therapy has been rec-
ognized as a risk factor for mortality. This assumption is not a
new paradigm since Ehrlich’s concept of “hit hard and fast” was
first described in the early 1900 (4). More recently, Kumar et al
(5) conducted in the United States and Canada a retrospec-
tive cohort study in 2,731 septic shock patients and found that
effective antimicrobial administration within the first hour of
documented hypotension was associated with 79.9% survival
to hospital discharge. Treatment protocols targeting the rapid
administration of appropriate antibiotics are now recognized
as a key measure in the initial care of patients presenting with
severe sepsis and septic shock (6).
Based on this evidence, the Surviving Sepsis Campaign
(SSC) Guidelines recommended that after the recognition of
severe sepsis or septic shock, IV broad-spectrum antibiotics
should be administered as early as possible and always within
1 hour (for patients identified on the general medical wards)
or 3 hours (for patients identified in the emergency depart-
ment [ED]) (7). Nevertheless, these results need to be con-
firmed and the optimal timing of antibiotic administration
remains uncertain in patients with sepsis. Therefore, the aim
of this study was to analyze the association between timing of
antibiotic administration and mortality to evaluate whether
an optimal time window for empiric antibiotic administration
could be found in these patients with severe sepsis and septic
shock. Because of the global nature of the SSC, we also aimed
to describe cultural differences in empiric antibiotic treatment
for severe sepsis and septic shock.
MATERIAL AND METHODS
Sites and Patient Selection
The process of participation in the SSC is described in detail
elsewhere (8). Eligible subjects were those admitted to an ICU
having a suspected site of infection, two or more systemic
inflammatory response syndrome criteria, and one or more
organ dysfunction criteria (9). Clinical and demographic
characteristics and time of presentation with severe sepsis or
septic shock criteria were collected for analysis of time-based
measures. Time of presentation was determined through chart
review and defined in instructions to site data collectors on
the Campaign website and educational materials. For patients
enrolled from the ED, the time of presentation was defined as
the time of triage. For patients admitted to the ICU from the
medical and surgical wards and for patients in the ICU at the
time of diagnosis, the time of presentation was determined by
chart review for the diagnosis of severe sepsis. The patient was
considered to have a nosocomial infection if severe sepsis or
septic shock was discovered in the ICU more than 72 hours
after admission or if severe sepsis or septic shock was discov-
ered in the ward and the patient had been in the ward more
than 72 hours prior to sepsis identification. Otherwise, the
patient was considered to have a community infection.
Data Collection
Data were entered into the SSC database locally at individual
hospitals into preestablished, unmodifiable fields document-
ing performance data and the time of specific actions and
findings. Data stripped of private health information were
submitted every 30 days to the secure master SSC server at the
Society of Critical Care Medicine (Mount Prospect, IL) via file
transfer protocol or as comma-delimited text files attached to
e-mail submitted to the Campaign’s server.
Institutional Review Board Approval
The global SSC improvement initiative was approved by the
Cooper University Hospital Institutional Review Board (Cam-
den, NJ) as meeting criteria for exempt status.
Analysis Set Construction
The analysis set was constructed from the subjects entered into
the SSC database from January 2005 through February 2010.
Inclusion was limited to sites with at least 20 subjects and at
least 3 months of subject enrollment.
Antibiotics and Time to Administration
Once severe sepsis or septic shock was identified using the
screening criteria established in the SSC initiative, patients
were eligible for antibiotics. All dates and times in the SSC
database are based on the time of presentation. Time to first
antibiotic administration is reported as the difference between
time of presentation (as recorded in the database and described
above) and first antibiotic administration (also entered into
the database through chart review by institutional data collec-
tor). For each antibiotic given to a particular patient, the name
of the antibiotic and time of administration were recorded
in the database. Patients could receive none, one, or multiple
antibiotics. Throughout the rest of this manuscript, antibiotic
administration implies the patient’s first antibiotic. Subjects
who did not receive any antibiotics in the first 6 hours, those
with missing time of antibiotic administration, or subjects
who were receiving antibiotics prior to presentation of severe
sepsis were excluded from the data analysis.
Statistical Analysis
Since the study’s goal was not to predict hospital mortal-
ity but rather to identify the role of timing of antibiotic
Copyright (c) Society of Critical Care Medicine and Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited
Feature Article
Critical Care Medicine www.ccmjournal.org 3
administration on survival, we used a risk factor modeling
approach to determine which covariates to add to the model—
a generalized estimating equation (GEE) population averaged
logistic regression. Logistic regression was used to analyze hos-
pital mortality since the database has complete information on
the time to antibiotic administration on all subjects and their
mortality status (no censoring). Time to only the patient’s first
antibiotics was entered into the model as a categorical vari-
able, and only covariates that acted as either a confounder or
an effect modifier were included. A confounder was identified
when its addition to the model changed the odds ratio associ-
ated with the time to antibiotic administration by more than
10% in either direction, without considering statistical signifi-
cance. A covariate that had a statistically significant interaction
(p < 0.05) with antibiotic administration was considered to be
an effect modifier. Table S1 (Supplemental Digital Content 1,
http://links.lww.com/CCM/A900) in the online appendix lists
the 51 covariates that were considered possible confounders
and effect modifiers. GEE population averaged logistic regres-
sion was used since patients are nested within a particular
ICU. This method takes into account the variability within
and between ICUs and uses this inherent correlation when
estimating the SEs that are used to test model coefficients. The
hierarchical nature of the SSC data lends itself to this type of
analysis. All analyses were run using Stata 12.1 (Stata Corpora-
tion, College Station, TX).
RESULTS
A total of 28,150 patients with severe sepsis and septic shock
from 165 ICUs were evaluated. Four hundred fifty-seven
patients (457) received no antibiotics, 832 received antibiotics
but were missing the timing of the antibiotics, and 8,871 patients
received antibiotics prior to suspected sepsis. These patients were
removed from the analysis set; thus, a total of 17,990 patients
received antibiotics and were
included in the analysis of time-
to-antibiotic administration and
mortality (Fig. 1).
Table 1 summarizes patient
characteristics by antibiotic
timing in 1-hour time peri-
ods up to 6 hours. All patients
that received antibiotics after 6
hours were grouped together
in this table since they only
represented 12% of the obser-
vations. Hospital mortality is
32.0% in the first hour of anti-
biotic administration, drops
to 28.1% in the second hours,
and then steadily increases after
that. It peaks at 39.6% in those
receiving antibiotics after 6
hours. The median sepsis sever-
ity score (SSS) is the highest in
the first hour compared with all other time points. The SSS
was developed and validated on the SSC database and includes
the elements available in the database such as location where
sepsis was suspected (ED, ward, or ICU), geographic loca-
tion (Europe, United States, South America), infection source
(pneumonia, urinary tract infection, abdominal, etc.), vari-
ous organ failures, hypotension (resolved and unresolved),
mechanical ventilation, and other clinical characteristics (T.
Osborn et al, unpublished observation, 2013). In the first hour,
patients tend to have a higher proportion of severe sepsis/septic
shock identified in the ICU (10.6%), compared with the same
patients in the other time periods, higher mortality (46.6%)
when severe sepsis/septic shock is identified in the ICU, higher
proportion of pulmonary organ failure (30.8%), higher pro-
portion of nosocomial infection (21.9%), higher septic shock
(69.6%), longer hospital and ICU length of stays (13 and 5.1 d,
respectively), and the lowest proportion of a single organ fail-
ure (40.1%). After 1 hour, hospital mortality steadily increases
with a delay in antibiotic timing. The prevalence of nosoco-
mial infection decreases during the first 3 hours of antibiotics
administration and then increases when administered after 4
hours. The proportion of patients with 1 baseline organ dys-
function is highest in the first hour and then decreases with a
delay in antibiotics.
Figure 2 and the odds ratios in Table 2 are based on the
same adjusted GEE population averaged logistic regression
model. The model is adjusted for SSS, ICU admission source
(ED, ward, vs ICU), and geographic region (Europe, United
States, and South America). The relationship between hospital
mortality and time to first antibiotic administration was fairly
robust once we controlled for these three covariates, thus no
additional covariates (for a list, see Table S1, Supplemental
Digital Content 1, http://links.lww.com/CCM/A900) either
confounded nor were effect modifiers of the relationship
between hospital mortality and time to first antibiotic. The
Figure 1. Patient enrollment diagram.
Copyright (c) Society of Critical Care Medicine and Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited
Ferrer et al
4 www.ccmjournal.org XXX2014•VolumeXX•NumberXXX
TABLE 1. Patient Characteristics by Timing in Hours to the First Antibiotic
Patient
Characteristic,
n (%)
Antibiotic Timing (Hr)
pa
0.0–1.0 1.0–2.0 2.0–3.0 3.0–4.0 4.0–5.0 5.0–6.0 > 6.0
n4,728 4,595 3,020 1,734 1,037 640 2,239
Hospital mortality 1,512 (32.0) 1,292 (28.1) 863 (28.6) 517 (29.8) 337 (32.5) 234 (36.6) 885 (39.6) < 0.001
Severity sepsis
score, median
(IQR)
58 (42–73) 50 (36–66) 49 (35–64) 49 (35–66) 51 (37–68) 53 (38–69) 57 (40–71) < 0.001
Nosocomial
infection
812 (17.2) 357 (7.8) 229 (7.6) 173 (10.0) 128 (12.3) 89 (13.9) 403 (18.0) < 0.001
Septic shock 3,289 (69.6) 2,880 (62.7) 1,847 (61.2) 1,047 (60.4) 684 (66.0) 441 (68.9) 1,370 (61.3) < 0.001
Hospital LOS,
median days
(IQR)
13 (6.4–25) 10 (5.6–19) 10.0 (5.6–19) 11 (5.9–20) 12 (5.9–23) 12 (6.3–22) 14 (7.3–29) < 0.001
ICU LOS, median
days (IQR)
5.1 (2.4–11) 4.1 (2.1–8.9) 4.2 (2.1–8.8) 4.3 (2.0–9.5) 4.9 (2.4–11) 4.6 (2.1–10) 6.7 (2.8–15) < 0.001
LOS prior to ICU,
median days
(IQR)
0.1 (0.0–0.8) 0.1 (0.0–0.3) 0.1 (0.0–0.3) 0.1 (0.0–0.4) 0.2 (0.0–0.5) 0.2 (0.0–0.7) 0.2 (0.0–1.4) < 0.001
Location where sepsis identified
ED 3,028 (64.0) 3,716 (80.9) 2,424 (80.3) 1,322 (76.2) 727 (70.1) 417 (65.2) 1,294 (57.9) < 0.001
ED mortality 797 (26.3) 935 (25.2) 629 (26.0) 352 (26.6) 209 (28.8) 132 (31.7) 404 (31.2) < 0.001
Ward 1,198 (25.3) 680 (14.8) 469 (15.5) 326 (18.8) 244 (23.5) 177 (27.7) 689 (30.8) < 0.001
Ward mortality 481 (40.2) 274 (40.3) 195 (41.6) 131 (40.8) 94 (38.5) 83 (46.9) 332 (48.2) < 0.001
ICU 502 (10.6) 199 (4.3) 127 (4.2) 86 (5.0) 66 (6.4) 46 (7.2) 253 (11.3) < 0.001
ICU mortality 234 (46.6) 83 (41.7) 39 (30.7) 34 (39.5) 34 (51.5) 19 (41.3) 149 (58.9) < 0.001
Site of infection
Pneumonia 2,388 (50.5) 2,308 (50.2) 1,398 (46.3) 729 (42.0) 430 (41.5) 252 (39.4) 982 (43.9) < 0.001
Urinary tract
infection
1,076 (22.8) 1,332 (29.0) 950 (31.5) 518 (29.9) 273 (26.3) 164 (25.6) 444 (19.9) < 0.001
Abdominal 914 (19.3) 738 (16.1) 545 (18.1) 387 (22.3) 225 (21.7) 146 (22.8) 550 (24.6) < 0.001
Meningitis 101 (2.1) 57 (1.2) 39 (1.3) 23 (1.3) 16 (1.5) 5 (0.8) 36 (1.6) 0.002
Skin 294 (6.2) 294 (6.4) 212 (7.0) 119 (6.9) 66 (6.4) 35 (5.5) 113 (5.1) 0.040
Bone 46 (1.0) 57 (1.2) 48 (1.6) 28 (1.6) 7 (0.7) 9 (1.4) 37 (1.7) 0.075
Wound 206 (4.4) 242 (5.3) 124 (4.1) 78 (4.5) 50 (4.8) 20 (3.1) 95 (4.3) 0.080
Catheter 169 (3.6) 157 (3.4) 106 (3.5) 75 (4.3) 37 (3.6) 29 (4.5) 88 (3.9) 0.596
Endocarditis 46 (1.0) 42 (0.9) 33 (1.1) 15 (0.9) 14 (1.4) 11 (1.7) 26 (1.2) 0.548
Device 54 (1.1) 51 (1.1) 43 (1.4) 24 (1.4) 16 (1.5) 9 (1.4) 22 (1.0) 0.704
Other infection 260 (9.7) 528 (11.5) 399 (13.2) 216 (12.5) 145 (14.0) 95 (14.8) 337 (15.7) < 0.001
Baseline acute organ dysfunction
Cardiovascular 4,221 (89.3) 4,123 (89.7) 2,689 (89.0) 1,510 (87.1) 888 (85.6) 541 (84.5) 1,800 (80.5) < 0.001
Pulmonary 1,456 (30.8) 1,120 (24.4) 610 (20.2) 383 (22.1) 240 (23.1) 145 (22.7) 681 (30.5) < 0.001
Renal 1,824 (38.6) 1,717 (37.4) 1,139 (37.7) 644 (37.1) 415 (40.0) 238 (37.2) 890 (39.8) 0.002
Hepatic 393 (8.3) 415 (9.0) 285 (9.4) 170 (9.8) 107 (10.3) 74 (11.6) 280 (12.5) < 0.001
Hematologic 1,171 (24.8) 904 (19.7) 706 (23.4) 405 (23.4) 251 (24.2) 175 (27.3) 595 (26.6) < 0.001
(
Continued
)
Copyright (c) Society of Critical Care Medicine and Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited
Feature Article
Critical Care Medicine www.ccmjournal.org 5
regression model uses the same seven time periods as shown in
Table 1. Figure 2 illustrates the trend in hospital mortality over
timing to first antibiotic, relative to suspicion of sepsis. Table 2
shows that the adjusted hospital mortality odds ratios steadily
increase from 1.00 to 1.52 as time to antibiotic administration
increases from 0 to greater than 6 hours where 0–1 hour is the
referent group. The probability of mortality increases from
24.6% to 33.1% and is based on a subject having the following
characteristics: from the United States, admission source is the
ED, and the SSS is 52 (median of all observations).
DISCUSSION
The results of this study confirm, in the largest population
of patients with severe sepsis and septic shock reported to
date, that delay in antibiotic administration was associated
with increased in-hospital mortality. In addition, we confirm
the increasing risk associated with delay—there was a linear
increase in the risk of mortality for each hour delay in anti-
biotic administration from the first through the sixth hour
after patient identification This relationship between delay
in antibiotic administration and mortality has been demon-
strated before by Kumar et al (5). However, the population in
that study was patients with septic shock, and the delay was
from the onset of hypotension. Our study findings are distinct
and unique in the population studied and the location of these
patients in the hospital: similar results were found in patients
with either severe sepsis or septic shock, and consistent results
were also seen when patients were stratified by severity (num-
ber of organ failure) and whether sepsis was identified in the
ED, on the wards, or in the ICU. This study demonstrates, for
Number of acute organ dysfunction
1 1,898 (40.1) 2,078 (45.2) 1,363 (45.1) 777 (44.8) 458 (44.2) 275 (43.0) 942 (42.1)
< 0.001
2 1,653 (35.0) 1,587 (34.5) 1,060 (35.1) 608 (35.1) 358 (34.5) 227 (35.5) 732 (32.7)
3 847 (17.9) 681 (14.8) 436 (14.4) 268 (15.5) 154 (14.9) 99 (15.5) 387 (17.3)
4 265 (5.6) 207 (4.5) 131 (4.3) 68 (3.9) 51 (4.9) 31 (4.8) 134 (6.0)
5 65 (1.4) 42 (0.9) 30 (1.0) 13 (0.8) 16 (1.5) 8 (1.3) 41 (1.8)
Cardiovascular
No cardiovascular
dysfunction
376 (7.9) 379 (8.3) 265 (8.8) 168 (9.7) 115 (11.1) 57 (8.9) 349 (15.6)
< 0.001
Cardiovascular
dysfunction no
hypertension
803 (17.0) 1,004 (21.8) 659 (21.8) 402 (23.2) 174 (16.8) 116 (18.1) 403 (18.0)
Total shock 3,549 (75.1) 3,212 (69.9) 2,096 (69.4) 1,164 (67.2) 748 (72.1) 467 (73.0) 1,484 (66.4)
Lactate > 4 260 (5.5) 332 (7.2) 249 (8.3) 117 (6.8) 64 (6.2) 26 (4.1) 114 (5.1)
Vasopressors
only
2,273 (48.1) 1,938 (42.2) 1,309 (43.3) 769 (44.4) 522 (50.3) 346 (54.1) 1,126 (50.4)
Lactate > 4 and
vasopressors
1,016 (21.5) 942 (20.5) 538 (17.8) 278 (16.0) 162 (15.6) 95 (14.8) 244 (10.9)
IQR = interquartile range, LOS = length of stay, ED = emergency department.
ap value based on Pearson chi-square test for categorical variables and Wilcox rank-sum test for continuous variables.
TABLE 1. (Continued). Patient Characteristics by Timing in Hours to the First Antibiotic
Patient
Characteristic,
n (%)
Antibiotic Timing (Hr)
pa
0.0–1.0 1.0–2.0 2.0–3.0 3.0–4.0 4.0–5.0 5.0–6.0 > 6.0
Figure 2. Predicted hospital mortality and the associated 95% CIs for
time to first antibiotic administration. The results are adjusted by the sepsis
severity score (SSS), ICU admission source (emergency department [ED],
ward, vs ICU), and geographic region (Europe, United States, and South
America). Probability of hospital mortality is based on the subject having
the following specific characteristics: the patient is from the United States,
admission source is the ED, and the SSS is 52 (median of all observations).
Copyright (c) Society of Critical Care Medicine and Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited
Ferrer et al
6 www.ccmjournal.org XXX2014•VolumeXX•NumberXXX
the first time, that delay in antibiotic administration has a sig-
nificant negative impact on survival across all areas in the hos-
pital and across levels of illness severity (organ dysfunction).
The most important finding from our study is the sur-
vival benefit associated with prompt antibiotic administration
in severe sepsis and septic shock. The potential influence of
delayed antibiotic therapy was first evaluated in patients with
community-acquired pneumonia. In the early-1990, McGarvey
and Harper (10) demonstrated that care processes that included
antibiotic delivery within 4 hours were associated with lower
pneumonia mortality at two community hospitals. More
recently, Houck et al (11) described that among 13,771 patients
who had not received outpatient antibiotic agents, antibiotic
administration within 4 hours of arrival at the hospital was
associated with reduced in-hospital mortality (6.8% vs 7.4%;
adjusted odds ratio [AOR], 0.85; 95% CI, 0.74–0.98) and mor-
tality within 30 days of admission (11.6% vs 12.7%; AOR, 0.85;
95% CI, 0.76–0.95). Kahn et al (12) observed a 4% point reduc-
tion in 30-day mortality among Medicare patients who received
antibiotics within 4 hours of admission and appropriate oxygen
therapy. Interestingly, this work highlights not only the early
administration of antibiotics but also correlates the process of
care with better outcomes. In a study of 261 patients in the ED,
Gaieski et al (13) confirmed the association with timing of anti-
biotic therapy and mortality in patients with severe sepsis or
septic shock. In our previous prospective observational study in
77 ICUs (14) based on propensity scores and adjusting for other
treatments, we reported that among 2,796 severe sepsis/septic
shock patients, empiric antibiotic treatment reduced mortality
(treatment within 1 hr vs no treatment within first 6 hr of diag-
nosis; odds ratio, 0.67; 95% CI, 0.50–0.90; p = 0.008). Kumar
et al (5) demonstrated that every additional hour without anti-
biotics increased the risk for death in septic shock patients by
7.6% during the first 6 hours. It is important to point out that
this was a retrospective study over 15 years, and recruitment
rates were relatively low, with 2,154 patients included from 10
sites (14 ICUs). Only 12% of patients had received antibiotics
within the first hour. In addition, Kumar et al (5) focused on
septic shock patients with appropriate antibiotic treatment. Our
data demonstrate that the association between timing of antibi-
otic administration and mortality is not only true for patients
with septic shock but also for patients with severe sepsis.
The relationship of prompt antibiotic and better outcomes
might represent a surrogate marker for the quality of care in a
broader sense. Other important sepsis treatments have shown
time-dependency, like quantitative resuscitation (15) or source
control (16). In fact, the meta-analysis of Barochia et al (3)
showed that the implementation of SSC bundles was followed
by an improvement in most of the sepsis process-of-care vari-
ables, including time-to-antibiotic treatment, followed by a
mortality reduction.
Recent studies report low compliance with prompt adminis-
tration of antimicrobial therapy. In these reports, although the
SSC proposals were implemented, the mean delay to first infusion
of antibiotics remained in excess of 3 hours (17), and as many as
68% of patients did not receive their first dose within this period
(18). In addition, Kumar et al (5) reported that delays in adminis-
tration of antibiotics are common: 79% of patients did not receive
antibiotics until the onset of hypotension, and of those patients,
only 14.5% received them within the first hour of hypotension.
Only 32.5% received antibiotics by 3 hours and only 51.4% by 6
hours. It is important to note here that there is controversy about
performance metrics for antibiotic timing in patients with pneu-
monia. In a retrospective review of patients with community-
acquired pneumonia, Welker et al (19) demonstrated that while
performance metrics decreased time to first antibiotic dose from
8 to 4 hours, there was also an associated reduction in the accuracy
of diagnosis of pneumonia by ED physicians.
TABLE 2. Adjusted Hospital Mortality Odds Ratio and Probability of Mortality for Time to
Antibiotics Based on a Generalized Estimating Equation Population Averaged Logistic
Regression Model
Time to
Antibiotics (Hr) ORa95% CI p
Probability of
Mortality (%)b95% CI
0–1c1.00 24.6 23.2–26.0
1–2 1.07 0.97–1.18 0.165 25.9 24.5–27.2
2–3 1.14 1.02–1.26 0.021 27.0 25.3–28.7
3–4 1.19 1.04–1.35 0.009 27.9 25.6–30.1
4–5 1.24 1.06–1.45 0.006 28.8 25.9–31.7
5–6 1.47 1.22–1.76 < 0.001 32.3 28.5–36.2
> 6 1.52 1.36–1.70 < 0.001 33.1 30.9–35.3
OR = odds ratio.
aHospital mortality odds ratio referent group is 0–1 hr for the time to antibiotics and is adjusted by the sepsis severity score (SSS), ICU admission source (ED,
ward, vs ICU), and geographic region (Europe, United States, and South America).
bProbability of hospital mortality is estimated using the generalized estimating equation population averaged logistic regression model and is based on the
subject having the following characteristics: from the United States, admission source is the ED, and the SSS is 52 (median of all observations).
cAntibiotics administered in the first hour are the referent group and thus the odds ratio by definition is 1.00 while the 95% CI and the p value are not generated
by the regression model.
Copyright (c) Society of Critical Care Medicine and Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited
Feature Article
Critical Care Medicine www.ccmjournal.org 7
Our study has several limitations. As with any retrospec-
tive study, there is potential for residual confounding. Second,
in our report, the main goal of the study was to evaluate only
timing of initial antibiotic administration and not appropriate-
ness since this variable is commonly based on culture data avail-
able only after 24–96 hours. Therefore, we could not assess the
appropriateness of antibiotic therapy in this patient population.
Inappropriate or inadequate antibiotic choices may confound
our results. Current SSC guidelines recommend administra-
tion of broad-spectrum antibiotics, and our results demonstrate
adherence to this recommendation, which might reduce, but not
eliminate the likelihood of inadequate coverage. Additionally,
this was a retrospective review that did not allow for analysis
of the reasons for delay or the cause of the delay in antibiotic
administration. We are unable, in the SSC database, to ascertain
whether the delay in antibiotic administration was because of
order writing, pharmacy delay, or other system factors.
In conclusion, this study demonstrates a significant associa-
tion between delay in antibiotic administration over the first
6 hours after identification of patients with severe sepsis and
septic shock and increasing mortality. These results underscore
the importance of early identification and treatment of septic
patients in the hospital setting. As mentioned often in the lit-
erature, sepsis is a time-dependent condition (like acute myo-
cardial infarction or stroke) and should be recognized as an
urgent situation that requires immediate response.
REFERENCES
1. Martin GS, Mannino DM, Eaton S, et al: The epidemiology of sepsis
in the United States from 1979 through 2000. N Engl J Med 2003;
348:1546–1554
2. Angus DC, Linde-Zwirble WT, Lidicker J, et al: Epidemiology of severe
sepsis in the United States: Analysis of incidence, outcome, and
associated costs of care. Crit Care Med 2001; 29:1303–1310
 3.BarochiaAV,CuiX,VitbergD,et al:Bundledcareforseptic shock:
An analysis of clinical trials. Crit Care Med 2010; 38:668–678
4. Ehrlich P: Chemotherapeutics: Scientific principles, methods, and
results. Address in pathology to 17th International Congress of
Medicine (London, 1913). Lancet 1913; 2:445–451
5. Kumar A, Roberts D, Wood KE, et al: Duration of hypotension before
initiation of effective antimicrobial therapy is the critical determinant of
survival in human septic shock. Crit Care Med 2006; 34:1589–1596
6. Puskarich MA, Trzeciak S, Shapiro NI, et al; Emergency Medicine
Shock Research Network (EMSHOCKNET): Association between
timing of antibiotic administration and mortality from septic shock in
patients treated with a quantitative resuscitation protocol. Crit Care
Med 2011; 39:2066–2071
7. Dellinger RP, Levy MM, Carlet JM, et al; International Surviving
Sepsis Campaign Guidelines Committee; American Association
of Critical-Care Nurses; American College of Chest Physicians;
American College of Emergency Physicians; Canadian Critical
Care Society; European Society of Clinical Microbiology and
Infectious Diseases; European Society of Intensive Care Medicine;
European Respiratory Society; International Sepsis Forum; Japanese
Association for Acute Medicine; Japanese Society of Intensive Care
Medicine; Society of Critical Care Medicine; Society of Hospital
Medicine; Surgical Infection Society; World Federation of Societies
of Intensive and Critical Care Medicine: Surviving Sepsis Campaign:
International guidelines for management of severe sepsis and septic
shock: 2008. Crit Care Med 2008; 36:296–327
8. Levy MM, Dellinger RP, Townsend SR, et al; Surviving Sepsis
Campaign: The Surviving Sepsis Campaign: Results of an interna-
tional guideline-based performance improvement program targeting
severe sepsis. Crit Care Med 2010; 38:367–374
9. Levy MM, Fink MP, Marshall JC, et al; International Sepsis Definitions
Conference: 2001 SCCM/ESICM/ACCP/ATS/SIS International
Sepsis Definitions Conference. Intensive Care Med 2003; 29:530–538
10. McGarvey RN, Harper JJ: Pneumonia mortality reduction and qual-
ity improvement in a community hospital. QRB Qual Rev Bull 1993;
19:124–130
11. Houck PM, Bratzler DW, Nsa W, et al: Timing of antibiotic admin-
istration and outcomes for Medicare patients hospitalized with
community-acquired pneumonia. Arch Intern Med 2004; 164:637–644
12.Kahn KL, Rogers WH, Rubenstein LV, et al: Measuring quality of
care with explicit process criteria before and after implementa-
tion of the DRG-based prospective payment system. JAMA 1990;
264:1969–1973
13. Gaieski DF, Mikkelsen ME, Band RA, et al: Impact of time to antibiot-
ics on survival in patients with severe sepsis or septic shock in whom
early goal-directed therapy was initiated in the emergency depart-
ment. Crit Care Med 2010; 38:1045–1053
14. Ferrer R, Artigas A, Suarez D, et al; Edusepsis Study Group:
Effectiveness of treatments for severe sepsis: A prospective, multicenter,
observational study. Am J Respir Crit Care Med 2009; 180:861–866
15. Rivers E, Nguyen B, Havstad S, et al; Early Goal-Directed Therapy
Collaborative Group: Early goal-directed therapy in the treatment of
severe sepsis and septic shock. N Engl J Med 2001; 345:1368–1377
16. Wong CH, Chang HC, Pasupathy S, et al: Necrotizing fasciitis:
Clinical presentation, microbiology, and determinants of mortality.
J Bone Joint Surg Am 2003; 85-A:1454–1460
17. Sebat F, Musthafa AA, Johnson D, et al: Effect of a rapid response
system for patients in shock on time to treatment and mortality during
5 years. Crit Care Med 2007; 35:2568–2575
18.De Miguel-YanesJ M, Andueza-Lillo JA, González-Ramallo VJ, et al:
Failure to implement evidence-based clinical guidelines for sepsis at
the ED. Am J Emerg Med 2006; 24:553–559
19. Welker JA, Huston M, McCue JD: Antibiotic timing and errors in diag-
nosing pneumonia. Arch Intern Med 2008; 168:351–356
... Depending on their experience, clinicians administer broad-spectrum antibiotics as soon as sepsis is identified clinically. Numerous studies have demonstrated that the rapid administration of antimicrobial drugs that target the underlying pathogen can considerably enhance patient care and survival [7][8][9], but conventional diagnostic approaches do not permit rapid pathogen diagnosis. Blood culture is the gold standard for diagnosing pathogens in clinical practice, but it is timeconsuming, and some bacteria may go undetected due to a variety of factors. ...
Article
Full-text available
Sepsis is one of the possible outcomes of severe trauma, and it poses a dire threat to human life, particularly in immunocompromised people. The most prevalent pathogens are bacteria and fungi, but viruses should not be overlooked. For viral metagenomic analysis, we collected blood samples from eight patients with post-traumatic sepsis before and seven days after treatment. The results demonstrated that Anellovirus predominated the viral community, followed by Siphoviridae and Myoviridae, and that the variations in viral community and viral load before and after treatment were not statistically significant. This study allows us to investigate methods for establishing NGS-based viral diagnostic instruments for detecting viral infections in the blood of sepsis patients so that antiviral therapy can be administered quickly.
... pneumoniae) and up to 40% CR in Escherichia coli (E.coli). 2 The emergence and spread of CR in gram-negative bacteria (GNB) including Enterobacteriaceae forces the physician to choose empiric coverage for carbapenem-resistant GNB (CR-GNB) with drugs such as polymyxins, which in turn becomes an independent risk factor for polymyxin resistant infections. [3][4][5][6] Rapid detection of CR in GNB sepsis, using novel molecular diagnostics well in advance of receipt of conventional culture and drug sensitivity testing (DST) would aid in antimicrobial stewardship. 7 Jauréguy et al. studied culture samples spiked with carbapenemase producing isolates to detect CR genes (KPC, NDM, VIM, OXA-48, and IMP-1) and found 100 percent agreement with genes already characterized. ...
... Another significant finding from our data is that administering meropenem through continuous infusion, preceded by a loading dose, achieves therapeutic concentrations in most patients within a few hours of commencing meropenem therapy. This approach ensures continuous exposure to drug concentrations that exceed the MIC and effectively combats the pathogens from the early stages of infection, which is crucial for improving the clinical outcome of the patient [26][27][28][29]. In addition, the administration of meropenem throughout the dosing interval represents a good therapeutic strategy in order to maximize the time-dependent antimicrobial activity of beta-lactams, fostering the maintenance of drug serum concentration above the MIC (T > MIC). ...
Article
Full-text available
Background: Meropenem is a carbapenem antibiotic widely employed for serious bacterial infections. Therapeutic drug monitoring (TDM) is a strategy to optimize dosing, especially in critically ill patients. This study aims to show how TDM influences the management of meropenem in a real-life setting, not limited to intensive care units. Methods: From December 2021 to February 2022, we retrospectively analyzed 195 meropenem serum concentrations (Css). We characterized patients according to meropenem exposure, focusing on the renal function impact. Results: A total of 36% (n = 51) of the overall observed patients (n = 144) were in the therapeutic range (8–16 mg/L), whereas 64% (n = 93) required a meropenem dose modification (37 patients (26%) underexposed; 53 (38%) overexposed). We found a strong relationship between renal function and meropenem concentrations (correlation coefficient = −0.7; p-value < 0.001). We observed different dose-normalized meropenem exposure (Css/D) among renal-impaired (severe and moderate), normal, and hyperfiltrating patients, with a median (interquartile range) of 13.1 (10.9–20.2), 7.9 (6.1–9.5), 3.8 (2.6–6.0), and 2.4 (1.6–2.7), respectively (p-value < 0.001). Conclusions: Meropenem TDM in clinical practice allows modification of dosing in patients inadequately exposed to meropenem to maximize antibiotic efficacy and minimize the risk of antibiotic resistance, especially in renal alterations despite standard dose adaptations.
... Early treatment is one of the pillars of sepsis therapy [1], with many studies demonstrating worse outcomes when initiation of treatment is delayed [2,3]. Sepsis and its resultant long-term sequelae are a leading cause of critical illness and mortality worldwide. ...
Article
Full-text available
Early treatment is the mainstay of sepsis therapy. We suspected that early recognition of sepsis by prehospital healthcare providers may shorten the time for antibiotic administration in the emergency department. We retrospectively evaluated all patients above 18 years of age who were diagnosed with sepsis or severe infection in our emergency department between 2018 and 2020. We recorded the suspected diagnosis at the time of presentation, the type of referring healthcare provider, and the time until initiation of antibiotic treatment. Differences between groups were calculated using the Kruskal-Wallis rank sum test. Of the 277 patients who were diagnosed with severe infection or sepsis in the emergency department, an infection was suspected in 124 (44.8%) patients, and sepsis was suspected in 31 (11.2%) patients by referring healthcare providers. Time to initiation of antibiotic treatment was shorter in patients where sepsis or infection had been suspected prior to arrival for both patients with severe infections (p = 0.022) and sepsis (p = 0.004). Given the well-described outcome benefits of early sepsis therapy, recognition of sepsis needs to be improved. Appropriate scores should be used as part of routine patient assessment to reduce the time to antibiotic administration and improve patient outcomes.
... Early antibiotic treatment plays a central role in the treatment of sepsis (2). This is supported by studies showing that delayed antibiotic treatment is associated with increased sepsis mortality (3)(4)(5)(6)(7); however, early recognition of sepsis may be difficult due to the dynamic nature of the condition and heterogenic clinical presentation. Furthermore, treatment can be delayed by prehospital factors, as well as time for clinical assessment, prescription, and administration of antibiotic treatment after arrival at the hospital. ...
Article
Full-text available
OBJECTIVES To identify factors associated with antibiotic treatment delay in patients admitted with bloodstream infections (BSIs). DESIGN Retrospective cohort study. SETTING North Zealand Hospital, Denmark. PATIENTS Adult patients with positive blood cultures obtained within the first 48 hours of admission between January 1, 2015, and December 31, 2015 ( n = 926). MEASUREMENTS AND MAIN RESULTS First recorded Early Warning Score (EWS), patient characteristics, time to antibiotic treatment, and survival at day 60 after admission were obtained from electronic health records and medicine module. Presence of contaminants and the match between the antibiotic treatment and susceptibility of the cultured microorganism were included in the analysis. Data were stratified according to EWS quartiles. Overall, time from admission to prescription of antibiotic treatment was 3.7 (3.4–4.0) hours, whereas time from admission to antibiotic treatment was 5.7 (5.4–6.1) hours. A gap between prescription and administration of antibiotic treatment was present across all EWS quartiles. Importantly, 23.4% of patients admitted with BSI presented with an initial EWS 0–1. Within this group of patients, time to antibiotic treatment was markedly higher among nonsurvivors at day 60 compared with survivors. Furthermore, time to antibiotic treatment later than 6 hours was associated with increased mortality at day 60. Among patients with an initial EWS of 0–1, 51.3% of survivors received antibiotic treatment within 6 hours, whereas only 19.0% of nonsurvivors received antibiotic treatment within 6 hours. CONCLUSIONS Among patients with initial low EWS, delay in antibiotic treatment of BSIs was associated with increased mortality at day 60. Lag from prescription to administration may contribute to delayed antibiotic treatment. A more frequent reevaluation of patients with infections with a low initial EWS and reduction of time from prescription to administration may reduce the time to antibiotic treatment, thus potentially improving survival.
Article
Full-text available
Background RNA methylation is closely involved in immune regulation, but its role in sepsis remains unknown. Here, we aim to investigate the role of RNA methylation-associated genes (RMGs) in classifying and diagnosing of sepsis. Methods Five types of RMGs (m1A, m5C, m6Am, m7G and Ψ) were used to identify sepsis subgroups based on gene expression profile data obtained from the GEO database (GSE57065, GSE65682, and GSE95233). Unsupervised clustering analysis was used to identify distinct RNA modification subtypes. The CIBERSORT, WGCNA, GO and KEGG analysis were performed to explore immune infiltration pattern and biological function of each cluster. RF, SVM, XGB, and GLM algorithm were applied to identify the diagnostic RMGs in sepsis. Finally, the expression levels of the five key RMGs were verified by collecting PBMCs from septic patients using qRT-PCR, and their diagnostic efficacy for sepsis was verified in combination with clinical data using ROC analysis. Results Sepsis was divided into three subtypes (cluster 1 to 3). Cluster 1 highly expressed NSUN7 and TRMT6 , with the characteristic of neutrophil activation and upregulation of MAPK signaling pathways. Cluster 2 highly expressed NSUN3 , and was featured by the regulation of mRNA stability and amino acid metabolism. NSUN5 and NSUN6 were upregulated in cluster 3 which was involved in ribonucleoprotein complex biogenesis and carbohydrate metabolism pathways. In addition, we identified that five RMGs ( NSUN7 , NOP2 , PUS1 , PUS3 and FTO ) could function as biomarkers for clinic diagnose of sepsis. For validation, we determined that the relative expressions of NSUN7 , NOP2 , PUS1 and PUS3 were upregulated, while FTO was downregulated in septic patients. The area under the ROC curve (AUC) of NSUN7 , NOP2 , PUS1 , PUS3 and FTO was 0.828, 0.707, 0.846, 0.834 and 0.976, respectively. Conclusions Our study uncovered that dysregulation of RNA methylation genes (m1A, m5C, m6Am, m7G and Ψ) was closely involved in the pathogenesis of sepsis, providing new insights into the classification of sepsis endotypes. We also revealed that five hub RMGs could function as novel diagnostic biomarkers and potential targets for treatment.
Article
Full-text available
Importance: The Sepsis Prediction Model (SPM) is a proprietary decision support tool created by Epic Systems; it generates a predicting sepsis score (PSS). The model has not undergone validation against existing sepsis prediction tools, such as Systemic Inflammatory Response Syndrome (SIRS), Sequential Organ Failure Assessment (SOFA), or quick Sepsis-Related Organ Failure Asessement (qSOFA). Objective: To assess the validity and timeliness of the SPM compared with SIRS, qSOFA, and SOFA. Design, setting, and participants: This retrospective cohort study included all adults admitted to 5 acute care hospitals in a single US health system between June 5, 2019, and December 31, 2020. Data analysis was conducted from March 2021 to February 2023. Main outcomes and measures: A sepsis event was defined as receipt of 4 or more days of antimicrobials, blood cultures collected within ±48 hours of initial antimicrobial, and at least 1 organ dysfunction as defined by the organ dysfunction criteria optimized for the electronic health record (eSOFA). Time zero was defined as 15 minutes prior to qualifying antimicrobial or blood culture order. Results: Of 60 507 total admissions, 1663 (2.7%) met sepsis criteria, with 1324 electronic health record-confirmed sepsis (699 [52.8%] male patients; 298 [22.5%] Black patients; 46 [3.5%] Hispanic/Latinx patients; 945 [71.4%] White patients), 339 COVID-19 sepsis (183 [54.0%] male patients; 98 [28.9%] Black patients; 36 [10.6%] Hispanic/Latinx patients; and 189 [55.8%] White patients), and 58 844 (97.3%; 26 632 [45.2%] male patients; 12 698 [21.6%] Black patients; 3367 [5.7%] Hispanic/Latinx patients; 40 491 White patients) did not meet sepsis criteria. The median (IQR) age was 63 (51 to 73) years for electronic health record-confirmed sepsis, 69 (60 to 77) years for COVID-19 sepsis, and 60 (42 to 72) years for nonsepsis admissions. Within the vendor recommended threshold PSS range of 5 to 8, PSS of 8 or greater had the highest balanced accuracy for classifying a sepsis admission at 0.79 (95% CI, 0.78 to 0.80). Change in SOFA score of 2 or more had the highest sensitivity, at 0.97 (95% CI, 0.97 to 0.98). At a PSS of 8 or greater, median (IQR) time to score positivity from time zero was 68.00 (6.75 to 605.75) minutes. For SIRS, qSOFA, and SOFA, median (IQR) time to score positivity was 7.00 (-105.00 to 08.00) minutes, 74.00 (-22.25 to 599.25) minutes, and 28.00 (-108.50 to 134.00) minutes, respectively. Conclusions and relevance: In this cohort study of hospital admissions, balanced accuracy of the SPM outperformed other models at higher threshold PSS; however, application of the SPM in a clinical setting was limited by poor timeliness as a sepsis screening tool as compared to SIRS and SOFA.
Article
Bacterially induced sepsis requires rapid bacterial detection and identification. Hours count for critically ill septic patients, while current culture-based detection requires at least 10 h up to several days. Here, we apply a microfluidic device equipped with a bacterially activated, macrophage-membrane-coating on nanowired-Si adsorbent surfaces for rapid, bacterial detection and Gram-identification in bacterially contaminated blood. Perfusion of suspensions of Gram-negative or Gram-positive bacteria through a microfluidic device equipped with membrane-coated adsorbent surfaces detected low (<10 CFU/mL) bacterial levels. Subsequent, in situ fluorescence-staining yielded Gram-identification for guiding antibiotic selection. In mixed Escherichia coli and Staphylococcus aureus suspensions, Gram-negative and Gram-positive bacteria were detected in the same ratios as those fixed in suspension. Results were validated with a 100% correct score by blinded evaluation (two observers) of 15 human blood samples, spiked with widely different bacterial strains or combinations of strains, demonstrating the potential of the platform for rapid (1.5 h in total) diagnosis of bacterial sepsis.
Article
Full-text available
The Surviving Sepsis Campaign (SSC or "the Campaign") developed guidelines for management of severe sepsis and septic shock. A performance improvement initiative targeted changing clinical behavior (process improvement) via bundles based on key SSC guideline recommendations on process improvement and patient outcomes. A multifaceted intervention to facilitate compliance with selected guideline recommendations in the ICU, ED, and wards of individual hospitals and regional hospital networks was implemented voluntarily in the US, Europe, and South America. Elements of the guidelines were "bundled" into two sets of targets to be completed within 6 h and within 24 h. An analysis was conducted on data submitted from January 2005 through March 2008. Data from 15,022 subjects at 165 sites were analyzed to determine the compliance with bundle targets and association with hospital mortality. Compliance with the entire resuscitation bundle increased linearly from 10.9% in the first site quarter to 31.3% by the end of 2 years (P<0.0001). Compliance with the entire management bundle started at 18.4% in the first quarter and increased to 36.1% by the end of 2 years (P = 0.008). Compliance with all bundle elements increased significantly, except for inspiratory plateau pressure, which was high at baseline. Unadjusted hospital mortality decreased from 37 to 30.8% over 2 years (P = 0.001). The adjusted odds ratio for mortality improved the longer a site was in the Campaign, resulting in an adjusted absolute drop of 0.8% per quarter and 5.4% over 2 years (95% CI, 2.5-8.4%). The Campaign was associated with sustained, continuous quality improvement in sepsis care. Although not necessarily cause and effect, a reduction in reported hospital mortality rates was associated with participation. The implications of this study may serve as an impetus for similar improvement efforts.
Article
Objective The Surviving Sepsis Campaign (SSC or “the Campaign”) developed guidelines for management of severe sepsis and septic shock. A performance improvement initiative targeted changing clinical behavior (process improvement) via bundles based on key SSC guideline recommendations on process improvement and patient outcomes.
Article
We developed explicit process criteria and scales for Medicare patients hospitalized with congestive heart failure, myocardial infarction, pneumonia, cerebrovascular accident, and hip fracture. We applied the process scales to a nationally representative sample of 14 012 patients hospitalized before and after the implementation of the diagnosis related group—based prospective payment system. For the four medical diseases, a better process of care resulted in lower mortality rates 30 days after admission. Patients in the upper quartile of process scores had a 30-day mortality rate 5% lower than that of patients in the lower quartile. The process of care improved after the introduction of the prospective payment system; eg, better nursing care after the introduction of the prospective payment system was associated with an expected decrease in 30-day mortality rates in pneumonia patients of 0.8 percentage points, and better physician cognitive performance was associated with an expected decrease in 30-day mortality rates of 0.4 percentage points. Overall, process improvements across all four medical conditions were associated with a 1 percentage point reduction in 30-day mortality rates after the introduction of the prospective payment system.(JAMA. 1990;264:1969-1973)
Article
Objective: To determine the incidence, cost, and outcome of severe sepsis in the United States. Design: Observational cohort study. Setting: All nonfederal hospitals (n = 847) in seven U.S. states. Patients: All patients (n = 192,980) meeting criteria for severe sepsis based on the International Classification of Diseases, Ninth Revision, Clinical Modification. Interventions: None. Measurements and Main Results : We linked all 1995 state hospital discharge records (n = 6,621,559) from seven large states with population and hospital data from the U.S. Census, the Centers for Disease Control, the Health Care Financing Administration, and the American Hospital Association. We defined severe sepsis as documented infection and acute organ dysfunction using criteria based on the International Classification of Diseases, Ninth Revision, Clinical Modification. We validated these criteria against prospective clinical and physiologic criteria in a subset of five hospitals. We generated national age- and gender-adjusted estimates of incidence, cost, and outcome. We identified 192,980 cases, yielding national estimates of 751,000 cases (3.0 cases per 1,000 population and 2.26 cases per 100 hospital discharges), of whom 383,000 (51.1%) received intensive care and an additional 130,000 (17.3%) were ventilated in an intermediate care unit or cared for in a coronary care unit. Incidence increased >100-fold with age (0.2/1,000 in children to 26.2/1,000 in those >85 yrs old). Mortality was 28.6%, or 215,000 deaths nationally, and also increased with age, from 10% in children to 38.4% in those >85 yrs old. Women had lower age-specific incidence and mortality, but the difference in mortality was explained by differences in underlying disease and the site of infection. The average costs per case were $22,100, with annual total costs of $16.7 billion nationally. Costs were higher in infants, nonsurvivors, intensive care unit patients, surgical patients, and patients with more organ failure. The incidence was projected to increase by 1.5% per annum. Conclusions: Severe sepsis is a common, expensive, and frequently fatal condition, with as many deaths annually as those from acute myocardial infarction. It is especially common in the elderly and is likely to increase substantially as the U.S. population ages.
Article
We sought to determine the association between time to initial antibiotics and mortality of patients with septic shock treated with an emergency department-based early resuscitation protocol. Preplanned analysis of a multicenter randomized controlled trial of early sepsis resuscitation. Three urban U.S. emergency departments. Adult patients with septic shock. A quantitative resuscitation protocol in the emergency department targeting three physiological variables: central venous pressure, mean arterial pressure, and either central venous oxygen saturation or lactate clearance. The study protocol was continued until all end points were achieved or a maximum of 6 hrs. Data on patients who received an initial dose of antibiotics after presentation to the emergency department were categorized based on both time from triage and time from shock recognition to initiation of antibiotics. The primary outcome was inhospital mortality. Of 291 included patients, mortality did not change with hourly delays in antibiotic administration up to 6 hrs after triage: 1 hr (odds ratio [OR], 1.2; 0.6-2.5), 2 hrs (OR, 0.71; 0.4-1.3), 3 hrs (OR, 0.59; 0.3-1.3). Mortality was significantly increased in patients who received initial antibiotics after shock recognition (n = 172 [59%]) compared with before shock recognition (OR, 2.4; 1.1-4.5); however, among patients who received antibiotics after shock recognition, mortality did not change with hourly delays in antibiotic administration. In this large, prospective study of emergency department patients with septic shock, we found no increase in mortality with each hour delay to administration of antibiotics after triage. However, delay in antibiotics until after shock recognition was associated with increased mortality.
Article
To study the association between time to antibiotic administration and survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Single-center cohort study. The emergency department of an academic tertiary care center from 2005 through 2006. Two hundred sixty-one patients undergoing early goal-directed therapy. None. Effects of different time cutoffs from triage to antibiotic administration, qualification for early goal-directed therapy to antibiotic administration, triage to appropriate antibiotic administration, and qualification for early goal-directed therapy to appropriate antibiotic administration on in-hospital mortality were examined. The mean age of the 261 patients was 59 +/- 16 yrs; 41% were female. In-hospital mortality was 31%. Median time from triage to antibiotics was 119 mins (interquartile range, 76-192 mins) and from qualification to antibiotics was 42 mins (interquartile range, 0-93 mins). There was no significant association between time from triage or time from qualification for early goal-directed therapy to antibiotics and mortality when assessed at different hourly cutoffs. When analyzed for time from triage to appropriate antibiotics, there was a significant association at the <1 hr (mortality 19.5 vs. 33.2%; odds ratio, 0.30 [95% confidence interval, 0.11-0.83]; p = .02) time cutoff; similarly, for time from qualification for early goal-directed therapy to appropriate antibiotics, a significant association was seen at the < or =1 hr (mortality 25.0 vs. 38.5%; odds ratio, 0.50 [95% confidence interval, 0.27-0.92]; p = .03) time cutoff. Elapsed times from triage and qualification for early goal-directed therapy to administration of appropriate antimicrobials are primary determinants of mortality in patients with severe sepsis and septic shock treated with early goal-directed therapy.
Article
Sepsis bundles have been developed to improve patient outcomes by combining component therapies. Valid bundles require effective components with additive benefits. Proponents encourage evaluation of bundles, both as a whole and based on the performance of each component. Assess the association between outcome and the utilization of component therapies in studies of sepsis bundles. Database searches (January 1980 to July 2008) of PubMed, Embase, and the Cochrane Library, using the terms sepsis, bundles, guidelines, and early goal directed therapy. Inclusion required comparison of septic adults who received bundled care vs. nonprotocolized care. Survival and use rates for individual interventions were abstracted. Eight unblinded trials, one randomized and seven with historical controls, were identified. Sepsis bundles were associated with a consistent (I2 = 0%, p = .87) and significant increase in survival (odds ratio, 1.91; 95% confidence interval, 1.49-2.45; p < .0001). For all studies reporting such data, there were consistent (I2 = 0%, p > or = .64) decreases in time to antibiotics, and increases in the appropriateness of antibiotics (p < or = .0002 for both). In contrast, significant heterogeneity was seen across trials for all other treatments (antibiotic use within a specified time period; administration of fluids, vasopressors, inotropes, and packed red blood cells titrated to hemodynamic goals; corticosteroids and human recombinant activated protein C use) (all I2 > or = 67%, p < .002). Except for antibiotics, sepsis bundle components are still being investigated for efficacy in randomized controlled trials. Bundle use was associated with consistent and significant improvement in survival and antibiotic use. Use of other bundle components changed heterogeneously across studies, making their impact on survival uncertain. However, this analysis should be interpreted cautiously as these studies were unblinded, and only one was randomized.